CHLD
CHANGE OF OWNER RECEIVED FROM IB
07/23/2026
Back to search
Official data from USPTO
AITEM
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
07/24/2026
Classification
Registered
Trademark type
Word
Nice classes
5, 42
Filing date
07/15/2022
Registration date
04/30/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/30/2024
Last transaction
07/24/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
98
Owner location
CN
Examiner
MATZINGER, AMY L
Law office
N90
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Metis TechBio Co., Ltd.
HANGZHOU JITAI PHARMACEUTICAL TECHNOLOGY CO.,LTD
BEIJING JITAI PHARMACEUTICAL TECHNOLOGY CO.,LTD
Representatives
MARK E. BANDY Rankin Hill & Clark, LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicines for human purposesfor use for central nervous system diseasesliver diseaseslung diseasescancersimmune system diseasesinfectious diseaseskidney and gastrointestinal diseases; Pharmaceutical preparationsfor use for central nervous system medicationsliver disease medicationslung disease medicationsanti-tumor medicationsimmune system medicationsanti-infective medicationskidney disease medicationsgastrointestinal medications; Chemico-pharmaceutical preparationsfor use for central nervous system medicationsliver disease medicationslung disease medicationsanti-tumor medicationsimmune system medicationsanti-infective medicationskidney disease medicationsgastrointestinal medications; Capsules being medicinescapsules for the treatment of central nervous system diseasesliver diseaseslung diseasescancersimmune system diseasesinfectious diseaseskidney related diseasesgastrointestinal diseases; Sedatives; Vaccines; Drugs for medical purposescentral nervous system medicationsliver disease medicationslung disease medicationsanti-tumor medicationsimmune system medicationsanti-infective medicationskidney disease medicationsgastrointestinal medications; Medicines in tablet formmedicinal preparations for the mouth to be applied in the form of tablets; Injectable medicinal solutionspowder for injectionparenteral solutionssolutions for injectionintravenous injectionssuspensions for injectionsterile powders for injectionintravenous injectionsemulsion for injectionemulsion injectionspowder injectionsconcentrated solutions for injectionall for the treatment of central nervous system diseasesliver diseaseslung diseasescancersimmune system diseasesinfectious diseaseskidney and gastrointestinal diseases; Pain relief medication; Immunostimulants; Pharmaceuticals for the treatment of cancer; Pharmaceuticals for the treatment of infectious diseases; Pharmaceuticals for the treatment of viral diseases; Medicinal preparations for the treatment of musculoskeletal disorders; Drugs and preparations for the treatment of gastrointestinal diseases; Medicinal preparations for skin diseases
Class 42
Design of computer databases; Conversion of computer programs and dataother than physical conversion; Digitization of documents being scanning; Computer programming in medical care; Providing virtual computer systems through cloud computing; Pharmaceutical drug development; Drug evaluation in the nature of evaluation and testing of illegal clandestine drug lab sites for the presence of hazardous and illegal materials; Pharmaceutical research; Scientific research and development; Conducting early evaluation of new drug fields in the nature of evaluation and testing of illegal clandestine drug lab sites for the presence of hazardous and illegal materials; Computer hardware design; Research and development of new products for others; Providing computer software design for others; Electronic data storage; Conducting technical project studies in the nature of technical research in the field of pharmaceutical studies; Conversion of data or documents from physical to electronic media; Clinical trialsscientific research in the nature of conducting clinical trials for others; Animal genetics research in the nature of studying the mechanism of action of compound combinations in animals; Computer programming
Publications
History of USPTO decisions and trademark events.
34 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/07/2024
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
10/27/2024
XXCR
GENERIC MADRID TRANSACTION CREATED
10/26/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
07/30/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/30/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
04/30/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
03/17/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/26/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
02/21/2024
GPNX
NOTIFICATION PROCESSED BY IB
02/19/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/13/2024
PUBO
PUBLISHED FOR OPPOSITION
02/13/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/29/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/24/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/24/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/10/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
01/04/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/04/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
01/04/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/04/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/08/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/08/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/08/2023
DOCK
ASSIGNED TO EXAMINER
11/19/2023
RFNP
REFUSAL PROCESSED BY IB
07/22/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/23/2023
RFRR
REFUSAL PROCESSED BY MPU
06/22/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/18/2023
CNRT
NON-FINAL ACTION WRITTEN
05/17/2023
DOCK
ASSIGNED TO EXAMINER
05/02/2023
MAFR
APPLICATION FILING RECEIPT MAILED
09/24/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/20/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/16/2022
Continuous trademark protection
Get notified about every new filing that threatens AITEM or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.